GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (STU:61Y) » Definitions » EV-to-FCF

Marinus Pharmaceuticals (STU:61Y) EV-to-FCF : -0.67 (As of Sep. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Marinus Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Marinus Pharmaceuticals's Enterprise Value is €75.12 Mil. Marinus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-111.45 Mil. Therefore, Marinus Pharmaceuticals's EV-to-FCF for today is -0.67.

The historical rank and industry rank for Marinus Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:61Y' s EV-to-FCF Range Over the Past 10 Years
Min: -9.23   Med: -3.31   Max: -0.25
Current: -0.7

During the past 12 years, the highest EV-to-FCF of Marinus Pharmaceuticals was -0.25. The lowest was -9.23. And the median was -3.31.

STU:61Y's EV-to-FCF is ranked worse than
100% of 396 companies
in the Biotechnology industry
Industry Median: 8.225 vs STU:61Y: -0.70

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-22), Marinus Pharmaceuticals's stock price is €1.45. Marinus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.462. Therefore, Marinus Pharmaceuticals's PE Ratio for today is At Loss.


Marinus Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Marinus Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals EV-to-FCF Chart

Marinus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.52 -5.15 -6.20 -0.29 -4.38

Marinus Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.77 -2.98 -4.38 -4.02 -0.48

Competitive Comparison of Marinus Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Marinus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinus Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Marinus Pharmaceuticals's EV-to-FCF falls into.



Marinus Pharmaceuticals EV-to-FCF Calculation

Marinus Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=75.118/-111.454
=-0.67

Marinus Pharmaceuticals's current Enterprise Value is €75.12 Mil.
Marinus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-111.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marinus Pharmaceuticals  (STU:61Y) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Marinus Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.45/-2.462
=At Loss

Marinus Pharmaceuticals's share price for today is €1.45.
Marinus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.462.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Marinus Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Marinus Pharmaceuticals Headlines

No Headlines